News | January 19, 2015

Hold Your Breath to Protect Your Heart

A simple technique may be most effective in preventing heart disease after radiation therapy for breast cancer

radiation therapy, breast cancer, breath hold, heart, clinical study

January 19, 2015 — Women who have breast cancer on their left side present a particular challenge to radiation oncologists. Studies have shown that the risk of heart disease is higher in this group of women after radiation treatment because it can be difficult to ensure that a sufficient dose of radiation is delivered to the left breast while adequately shielding the heart from exposure. New research shows a woman who holds her breath during radiation pulses can greatly reduce radiation exposure to the heart.

“Radiation therapy is commonly prescribed to patients with breast cancer following surgery as a component of first-line therapy,” said first author Harriet Eldredge-Hindy, M.D., a chief resident and researcher in the department of radiation oncology at Thomas Jefferson University. “We wanted to determine how effective breath-hold could be in shielding the heart from extraneous radiation exposure during treatment of the left breast.”

Recent studies have shown women with cancer in the left breast are at higher risk of heart disease, and that the risk increases proportionately with the dose of radiation the heart is exposed to during treatment. A number of techniques have been developed to reduce exposure to the heart including prone positioning, intensity-modulated radiation therapy (IMRT) and accelerated partial breast irradiation. The breath-hold technique allows doctors to monitor a patient’s breath for the position that shifts the heart out of the range of the radiation beam.

In the largest prospective study to date, following women for eight years post-treatment, 81 women were asked to hold their breath during radiation treatment for breast cancer– a process that was repeated until therapeutic dose was reached. The researchers found that patients capable of holding their breath over the course of treatment had a 90-percent disease-free survival, and a 96-percent overall survival, with a median reduction in radiation dose to the heart of 62 percent. The findings were published online in the journal Practical Radiation Oncology.

“Given that this technique helps to shield the heart during radiation treatment for breast cancer,” said Rani Anne, M.D., associate professor of radiation oncology at Thomas Jefferson University and senior author on the study, “we routinely offer breast cancer treatment with the breath-hold technique at Jefferson.”

Additional work presented at the 2014 American Society for Radiation Oncology in San Francisco carried the work further in order to determine whether protection from the additional radiation dose in fact translated to a reduction in ischemic heart disease. Anne, together with Eldredge-Hindy, showed that this same cohort of patients will likely have a reduced risk of ischemic heart disease after 10 years. The study showed that patients who held their breath during radiation therapy had only a 1.4-percent rate of ischemic heart disease after eight years of follow up and an estimated rate of 3.6 percent after 10 years.

For more information: www.jefferson.edu


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now